Timeline of Development

• Week 5-6: Pronephros appears and regresses
• Week 6-10: Mesonephros develops and functions transiently
• Week 5-36 weeks gestation: Metanephros develops; nephrogenesis continues until 36 weeks
• Birth: ~1 million nephrons per kidney; no new nephron formation after birth

Clinical Significance

• Developmental insults during critical windows cause permanent nephron loss
• The finite nephron endowment at birth determines lifelong renal reserve
• Early-life events (intrauterine growth restriction, premature birth) reduce nephron number

A. Pronephros (Pronephric Kidney)

Timeline: Week 5-6 of gestation

Anatomy: - Most rostral and simplest kidney system - 7-10 pronephric tubules - Located at cervical and thoracic levels - Drains via the pronephric duct (which becomes the mesonephric duct) - Primitive corpuscles with minimal filtration capability

Function: - Minimal functional significance in humans (unlike some amphibians and fish) - Primarily a developmental template

Clinical Relevance: - Embryologically important; pathologic mutations here rarely cause human disease - Understanding pronephric regression helps interpret genetic mutations affecting all three systems

B. Mesonephros (Wolffian Body)

Timeline: Week 6-10 (peaks at weeks 8-9)

Anatomy: - Intermediate kidney system; more complex than pronephros - 30-40 mesonephric tubules arranged segmentally - Located along the dorsal body wall at thoracic and lumbar levels - Mesonephric duct extends caudally - Glomeruli and tubular differentiation present

Function: - First functioning kidney in human fetus (weeks 9-12) - Produces ~14 mL/kg/day of urine in mid-gestation - Contributes to amniotic fluid volume - Gradually regresses as metanephros assumes function

Developmental Fate: - In males: Mesonephric duct (Wolffian duct) persists as: - Epididymis - Vas deferens - Seminal vesicles - Ejaculatory duct - In females: Regresses (müllerian duct develops instead)

Clinical Relevance: - Mesonephric duct abnormalities may cause ipsilateral reproductive tract anomalies (e.g., absent vas deferens with renal agenesis) - Mesonephric cysts occasionally persist into adulthood

C. Metanephros (Definitive Kidney)

Timeline: Week 5 (ureteric bud emergence) → 36 weeks gestation (nephrogenesis completion)

Origin of Components: - Ureteric bud (ureter and collecting system): Derives from mesonephric duct at week 5 - Metanephric mesenchyme (glomeruli and tubules): Derives from metanephric blastema (specialized intermediate mesoderm)

Development Sequence: 1. Ureteric bud extends dorsocranially into metanephric mesenchyme 2. Repeated branching creates major calyces (4-5 branches) → minor calyces → collecting ducts 3. Metanephric mesenchyme condenses around ureteric tips 4. Reciprocal induction drives nephrogenesis

A. GDNF/RET Signaling

Critical for ureteric bud development and branching

Mechanism: - GDNF (glial cell line-derived neurotrophic factor) expressed by metanephric mesenchyme - GDNF binds GFRα1 co-receptor on ureteric epithelium - Signal transduced via RET receptor tyrosine kinase - Promotes proliferation, survival, and branching of ureteric epithelium

Clinical Mutations: - RET mutations: Associated with bilateral renal agenesis or severe hypoplasia - GDNF mutations: Rare but associated with renal aplasia/hypoplasia - GFRα1 mutations: Oligonephronia (reduced nephron number)

Phenotypes: - Complete absence of ureteric bud → bilateral renal agenesis (incompatible with life unless transient) - Reduced GDNF/RET signaling → unilateral renal agenesis or hypoplasia

B. Wnt Signaling

Essential for both mesenchymal condensation and nephron differentiation

Mechanism: - Canonical Wnt/β-catenin pathway drives mesenchymal-epithelial transition - Wnt4 and Wnt9b critical for tubule formation - Temporal expression patterns regulate progression through developmental stages

Genes Involved: - Wnt4: Drives early epithelialization and S-shaped body formation - Wnt9b: Expressed by ureteric epithelium; regulates mesenchymal proliferation - Lrp6: Co-receptor; mutations cause cystic kidney disease

Clinical Manifestations: - Wnt4 mutations: Female pseudohermaphroditism (müllerian duct development), renal hypoplasia - Lrp6 mutations: Autosomal recessive cystic kidney disease with renal hypoplasia

C. BMP (Bone Morphogenetic Protein) Signaling

Regulates both positive and negative effects on nephrogenesis

Mechanism: - BMP7 promotes differentiation and tubule formation (pro-nephrogenic) - BMP4 can inhibit nephrogenesis in certain contexts (anti-nephrogenic) - Signaling through Smad proteins - Interaction with Wnt signaling for spatiotemporal regulation

Clinical Relevance: - BMP7 expression inversely correlates with renal fibrosis progression - Potential therapeutic target in CKD (anti-fibrotic effects)

D. FGF (Fibroblast Growth Factor) Signaling

Critical for mesenchymal expansion and branching

Key FGFs: - FGF7, FGF10: Secreted by surrounding mesenchyme; promote mesenchymal proliferation - FGF2: Regulates branching morphogenesis

Clinical Relevance: - Rare FGF receptor mutations associated with renal hypoplasia

E. WT1 (Wilms Tumor 1)

Transcription factor critical for genitourinary development

Functions: - Regulates mesenchymal condensation - Suppresses proliferation and promotes differentiation - Podocyte-specific gene in mature kidney

Mutations: - WT1 mutations: Wilms tumor, WAGR syndrome (Wilms, Aniridia, GU anomalies, Retardation), Denys-Drash syndrome (glomerulosclerosis + GU anomalies)

A. Ureteric Bud Development (Weeks 5-8)

1. Ureteric bud emerges from caudal mesonephric duct near Wolffian duct origin
2. Extends dorsocranially guided by GDNF gradient from mesenchyme
3. Undergoes iterative branching (15-20 generations)
4. Forms:
   • Ureter (distal portion of ureteric bud)
   • Major calyces (primary branches)
   • Minor calyces (secondary/tertiary branches)
   • Collecting ducts (final branches contact nephrons)

B. Mesenchymal Condensation and Nephron Formation (Weeks 6-36)

Six-stage developmental sequence:

Stage 1: Mesenchymal Condensation - Metanephric mesenchyme cells migrate toward ureteric tips - Condense into tight aggregates (cap mesenchyme) - Express pluripotent markers (Six2, Sall1)

Stage 2: Renal Vesicle Formation - Condensed mesenchyme cells undergo epithelialization - Form comma-shaped body (curved epithelial structure) - Early tubular commitment

Stage 3: S-Shaped Body - Comma-shaped body extends and loops into S-shape - Cellular differentiation into distinct zones: - Proximal (will form PCT) - Middle (will form LOH) - Distal (will form DCT)

Stage 4: Capillary Loop Stage - Endothelial cells invade the cleft of the S-shaped body - Form primitive capillary loop with podocyte precursors - Early glomerular differentiation

Stage 5: Mature Glomerulus Formation - Capillary loop elaboration with continued endothelial invasion - Podocytes undergo foot process differentiation - GBM deposition (type IV collagen, laminin, nidogen) - Filtration barrier maturation over weeks to months

Stage 6: Tubular Maturation - Proximal tubule cells: acquisition of brush border, transporters (NaKATPase, apical pumps) - Loop of Henle: development of specialized segments (descending and ascending thin limb, thick ascending limb) - Distal tubule and collecting duct: acquisition of principal and intercalated cells

C. Timing and Completion

• Nephrogenesis begins week 5 with ureteric bud emergence
• Peak rate of new nephron formation: weeks 20-24 gestation
• Rate declines progressively weeks 24-36
• Nephrogenesis ceases by 36 weeks gestation
• Maturation of glomeruli continues into early postnatal period

A. CAKUT Classification

Renal Parenchymal Anomalies:

1. Agenesis
   • Bilateral renal agenesis (incompatible with postnatal life; causes severe oligohydramnios)
   • Unilateral renal agenesis (isolated finding, compatible with normal life; 1:1000)
   • Etiology: Failure of ureteric bud emergence or early degeneration
2. Hypoplasia
   • Reduced nephron number and kidney mass
   • Progressive CKD risk even in absence of other renal disease
   • Subtypes:
     • Oligonephronia: Severe reduction in nephron number; typically unilateral
     • Segmental hypoplasia: Focal kidney area underdeveloped
3. Dysplasia
   • Abnormal differentiation; disorganized architecture
   • Primitive mesenchymal tissue persists
   • Cysts may be present (mixed dysplasia-cystic)
   • Often unilateral; bilateral involvement causes severe CKD

Collecting System Anomalies:

1. Hydronephrosis
   • Dilation of collecting system
   • Causes: Ureteropelvic junction (UPJ) obstruction, megaureter, obstruction at any level
   • Prenatal diagnosis increasingly common (improved ultrasound detection)
2. Duplex Systems
   • Complete: Separate ureteric buds → two ureters, two collecting systems
   • Incomplete: Bifid ureter or duplex collecting system with single ureteric orifice
   • Ectopic ureter in females: may cause incontinence (ureter inserts beyond urethral sphincter)
3. Ectopic Kidney
   • Abnormal final location (pelvic, thoracic, crossed ectopic)
   • Typically functions normally
   • Risk: Unrecognized during imaging; traumatic injury

Combined Parenchymal and Structural Anomalies:

1. VURD (Valves, Unilateral Reflux, Dysplasia)
   • Associated with posterior urethral valves in males
   • Contralateral kidney dysplasia common
2. Vesicoureteral Reflux (VUR)
   • Retrograde urine flow into ureter/kidney
   • Genetic predisposition; familial clustering observed
   • Increased infection risk; potential for renal scarring

B. Clinical Presentations and Outcomes

Prenatal Detection: - Ultrasound findings: Absent kidney, cystic changes, hydronephrosis - Polyhydramnios or oligohydramnios (depending on severity and timing)

Postnatal Outcomes by Anomaly:

A. Fundamental Principle

The Brenner hypothesis (proposed by Barry Brenner in the 1980s) posits that:

A reduced number of nephrons at birth predisposes to hypertension and progressive chronic kidney disease throughout adulthood.

B. Biological Mechanism

1. Reduced Single-Nephron GFR Compensation - Each remaining nephron must increase filtration to maintain total GFR - Hyperfiltration increases glomerular capillary pressure (elevated Pgg) - Chronic glomerular hypertension leads to sclerosis over time

2. Structural Consequences of Hyperfiltration - Glomerular enlargement (compensatory growth) - Podocyte damage and foot process effacement - Increased proteinuria (loss of size selectivity) - Glomerular sclerosis (irreversible)

3. Systemic Hypertension - Reduced renal mass → impaired sodium excretion → expanded intravascular volume - Activation of RAAS (decreased renal perfusion pressure triggers renin release) - Hypertension accelerates nephron loss

C. Clinical Evidence

Studies Supporting Brenner Hypothesis:

1. Autopsy studies: Patients with CKD or hypertension show lower mean nephron numbers than age-matched controls
2. Low birthweight cohorts: Reduced birthweight (proxy for reduced nephron number) associated with:
   • Higher blood pressure in childhood
   • Proteinuria development
   • Earlier CKD progression
3. IUGR and prematurity: Both independently reduce nephron endowment; associated with future hypertension and CKD
4. Animal models: Surgical reduction of renal mass (e.g., 5/6 nephrectomy) → progressive sclerosis in remaining nephrons

D. Clinical Applications

Screening and Identification: - Prenatal/neonatal diagnosis of renal agenesis, hypoplasia, dysplasia - Low birthweight infants (especially <2.5 kg) - Premature birth (<35 weeks) - Intrauterine growth restriction (IUGR)

Risk Stratification: - Nephron number (if estimable by imaging) predicts CKD risk - Combined with other factors (hypertension, proteinuria, obesity) stratifies progression risk

Preventive Management: - Aggressive blood pressure control in at-risk populations - ACE inhibitor/ARB therapy (renal protective beyond BP reduction) - Avoidance of NSAIDs and calcineurin inhibitors - Attention to metabolic risk factors (obesity, diabetes) - Lifestyle modification (sodium restriction, weight loss)

E. Developmental Origins of Adult Disease (DOHaD)

The Brenner hypothesis is part of a broader paradigm:

Intrauterine environment shapes lifelong renal health.

Factors affecting nephron endowment: - Maternal nutrition (protein deficiency, caloric restriction) - Maternal hypertension or preeclampsia - Fetal hypoxia (placental insufficiency, intrauterine growth restriction) - Maternal infections or substance exposure - Prematurity (incomplete nephrogenesis)

A. Renal Dysgenesis Progression

Even when initial function appears adequate, developmental kidney anomalies progress:

Mechanisms of Progressive Loss: 1. Sclerosis of dysplastic nephrons: Abnormal development → increased injury susceptibility 2. Glomerular hyperfiltration: Remaining functional nephrons bear excess burden 3. Tubular atrophy: Progressive loss of tubular epithelial cell viability 4. Interstitial fibrosis: Inflammatory response to chronic nephron loss

B. IUGR and Prematurity as Risk Factors

• IUGR: 30-50% reduction in nephron number; associated with hypertension in childhood
• Prematurity <32 weeks: Nephrogenesis not yet complete; accelerated loss postnatally
• Combined effect more severe than either alone

C. Intrauterine Exposure Effects

• Maternal caloric or protein restriction: Reduced metanephric mesenchyme proliferation
• Maternal hypertension/preeclampsia: Fetal renal perfusion compromise → reduced nephrogenesis
• In utero infections (e.g., CMV, rubella): Direct glomerular injury
• Maternal diabetes: Increased risk of congenital anomalies and reduced nephron number